Respiri

Overview
Price performance
Financials
Research
Thematics

Respiri is an ASX-listed company developing SaaS diagnostic solutions to support respiratory health management. Its technology detects wheeze, a typical symptom of asthma, chronic obstructive pulmonary disease and respiratory disease, to provide an objective measure of airway limitation.

Latest Insights

Healthcare |
Update

12.09.23

Respiri — Access platform-led growth prospects ahead

Healthcare |
Flash note

30.08.23

Respiri — Early onset of synergies from Access acquisition

Healthcare |
Flash note

14.08.23

Respiri — Raise anticipated to fund the Access acquisition

Healthcare |
Flash note

17.07.23

Respiri — wheezo to access a larger addressable market

Happy children launch a kite in the field at sunset. Little boy and girl on summer vacation

Visit Website

Sector

Healthcare

Balance Sheet

Forecast net debt (A$m)

0.7

Forecast gearing ratio (%)

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	4.2	(19.4)	(59.7)
Relative	1.8	(25.4)	(62.0)
52 week high/low	A$0.1/A$0.0

Financials

Edison Investment Research is terminating coverage on Respiri (RSH). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.